Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate.
作者信息
McMurray John
出版信息
BMJ. 2005 May 28;330(7502):1269; author reply 1270-1. doi: 10.1136/bmj.330.7502.1269.
Abstract
摘要
相似文献
1
Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate.
BMJ. 2005 May 28;330(7502):1269; author reply 1270-1. doi: 10.1136/bmj.330.7502.1269.
2
Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes.
BMJ. 2005 May 28;330(7502):1269-70; author reply 1270-1. doi: 10.1136/bmj.330.7502.1269-a.
3
Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed.
BMJ. 2005 May 28;330(7502):1270; author reply 1270-1. doi: 10.1136/bmj.330.7502.1270.
4
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
J Hypertens. 2008 Jul;26(7):1282-9. doi: 10.1097/HJH.0b013e328306ebe2.
5
ARBs vs ACE inhibitors for preventing diabetic nephropathy.
J Fam Pract. 2005 May;54(5):453; discussion 453-4.
6
ARBs and Myocardial Infarction.
Med Lett Drugs Ther. 2005 May 9;47(1208):38-9.
7
Have angiotensin receptor blockers lived up to expectations?
Can J Cardiol. 2005 May 15;21(7):569-75.
8
Angiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credible.
BMJ. 2005 May 28;330(7502):1270; author reply 1270-1. doi: 10.1136/bmj.330.7502.1270-a.
9
10
ARBs and mortality in myocardial infarction.
Cardiovasc J S Afr. 2005 Mar-Apr;16(2):84.
引用本文的文献
1
A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.
Vasc Health Risk Manag. 2011;7:297-313. doi: 10.2147/VHRM.S15541. Epub 2011 May 19.
2
Valsartan in the treatment of heart attack survivors.
Vasc Health Risk Manag. 2006;2(2):125-38. doi: 10.2147/vhrm.2006.2.2.125.
本文引用的文献
1
Angiotensin receptor blockers and myocardial infarction.
BMJ. 2004 Nov 27;329(7477):1248-9. doi: 10.1136/bmj.329.7477.1248.
2
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
N Engl J Med. 2003 Nov 13;349(20):1893-906. doi: 10.1056/NEJMoa032292. Epub 2003 Nov 10.
3
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.
Lancet. 2003 Sep 6;362(9386):759-66. doi: 10.1016/s0140-6736(03)14282-1.
4
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Ann Intern Med. 2003 Apr 1;138(7):542-9. doi: 10.7326/0003-4819-138-7-200304010-00010.
5
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.
Lancet. 2002 Sep 7;360(9335):752-60. doi: 10.1016/s0140-6736(02)09895-1.
Zotero 插件